Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 787.37

+3.4%

Nov 25 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	11/4/2015 7:01:26 AM
	Read Replies (1) of 3559

Regeneron earnings... November 4, 2015 Regeneron Reports Third Quarter 2015 Financial and Operating Results - Third quarter 2015 EYLEA® (aflibercept) Injection global net sales increased 53% to $1.105 billion (consisting of $734 million in the U.S. and $371 million in rest of world(1)) versus third quarter 2014 - Third quarter 2015 non-GAAP net income (2) increased 37% to $403 million, or $3.47 per diluted share, versus third quarter 2014 - Raised estimated full year 2015 EYLEA U.S. net sales growth guidance to 50% - 55% over 2014, from the previous guidance of 45% - 50% files.shareholder.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next